PINE BROOK, N.J.
Today, Alvogen has launched the first generic equivalent to Tamiflu® (oseltamivir phosphate) capsules in the United States. Alvogen expects the generic equivalent to Tamiflu® capsules to deliver significant savings for patients and health providers of up to $500 million during this upcoming season. The product is available in three strengths (30 mg, 45 mg and 75 mg).
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161212005289/en/
Alvogen Launches the First Generic Equivalent to Tamiflu® Capsules in the United States. Robert Wessman is the Chairman and CEO of Alvogen. (Photo: Business Wire)
Robert Wessman, Chairman and CEO of Alvogen, commented: “The launch of oseltamivir phosphate is great news for U.S. patients, who will finally have access to a more affordable alternative to Tamiflu. It is also an important milestone for our U.S. business. The launch demonstrates our ability to move quickly and we are proud to partner with Natco to bring this product to market.”
Alvogen currently has 79 products in development and pending FDA approval for the U.S. market. Annual brand sales for filed products and those under development have current brand sales exceeding $25 billion, according to IMS Health (2015).
A consortium of investors, led by CVC Capital Partners and including Singapore-based investment company Temasek and Vatera Healthcare Partners, acquired a majority stake in Alvogen in June 2015. Alvogen is currently one of the fastest growing pharmaceutical companies in the world, with a commercial presence in 35 countries and a well targeted portfolio of difficult-to-make generics and branded pharmaceuticals.
*Tamiflu is a registered trademark of Hoffman La-Roche Inc. Corporation. Alvogen is not affiliated with Hoffman La-Roche Inc.
About Alvogen
Alvogen is a global, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the-counter brands (OTC) and biosimilar products for patients around the world. The company has commercial operations in 35 countries with 2,300 employees and operates four manufacturing and development hubs in the U.S., Romania, Korea and Taiwan. North America is Alvogen’s single largest market and other key markets include: South Korea, Russia, Taiwan, Romania, Hungary, Ukraine, Japan and China.
Learn more about Alvogen on www.alvogen.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20161212005289/en/
CONTACT
Alvogen
Halldor Kristmannsson, (+354) 522 2900
Global
Corporate Marketing & Communications
halldor.kristmannsson@alvogen.com
